| Ticker: | VKTX |
| Current Price: | $29.22 |
| % Daily Change: | 5.95% |
| Volume (1,000s): | 8,855.52 |
| Average Volume (1,000s): | 2,397.93 |
| Market Cap (M): | $3,726.19 |
| 1/2/2024 Price: | $18.61 |
| Change Since Inception: | 57.01% |
Viking Therapeutics, Inc.
9920 Pacific Heights Boulevard
Suite 350
San Diego, CA 92121
United States
Viking Therapeutics, Inc. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. Our most advanced candidate is a non-steroidal selective androgen receptor modulator (SARM) currently in Phase 2 trial for the treatment recovery from hip fracture surgery. Our thyroid receptor beta (TRb) agonist platform, also in Phase 2, is being developed for lipid disorders such as hypercholesterolemia and fatty liver diseases such as non-alcoholic steatohepatitis (NASH) as well as for rare diseases of glycogen storage disease (GSD 1a) and X-linked adrenoleukodystrophy, or X-ALD.